BP
RMD icon

Ballentine Partners’s ResMed RMD Stock Holding History

Ballentine Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Sell
1,877
-1,686
-47% -$349K ﹤0.01% 693
2026
Q1 		$800K Buy
3,563
+1,609
+82% +$401K 0.01% 405
2025
Q4 		$471K Sell
1,954
-70
-3% -$17.9K 0.01% 523
2025
Q3 		$554K Sell
2,024
-31
-2% -$8.47K 0.01% 466
2025
Q2 		$530K Buy
2,055
+273
+15% +$65.1K 0.01% 463
2025
Q1 		$399K Buy
1,782
+105
+6% +$24.5K 0.01% 520
2024
Q4 		$384K Buy
1,677
+14
+0.8% +$3.37K 0.01% 506
2024
Q3 		$406K Buy
1,663
+31
+2% +$6.93K 0.01% 484
2024
Q2 		$312K Buy
1,632
+87
+6% +$17.7K 0.01% 544
2024
Q1 		$306K Buy
1,545
+248
+19% +$45.4K 0.01% 531
2023
Q4 		$223K Buy
+1,297
New +$199K ﹤0.01% 590
2023
Q3 		– Sell
-2,139
Closed -$467K – 641
2023
Q2 		$467K Buy
2,139
+43
+2% +$9.58K 0.01% 330
2023
Q1 		$459K Buy
+2,096
New +$455K 0.01% 314

Other funds holding RMD

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AC
Addenda Capital Montreal, Quebec, Canada $3.68B AUM 32.88% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

Ballentine Partners's RMD Position: Q2 2026 in Review

Ballentine Partners reduced its ResMed (RMD) stake by 47% in Q2 2026, selling an estimated $349K and leaving 1,877 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Ballentine Partners first reported a position in RMD in Q1 2023 and has held it in 13 quarters since. The position peaked at $800K in Q1 2026. 103 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Ballentine Partners held 1,877 shares of ResMed worth $366K as of Q2 2026.
  • Ballentine Partners sold 1,686 ResMed shares in Q2 2026, an estimated $349K.
  • ResMed made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #693 holding.
  • Ballentine Partners first reported a position in ResMed in Q1 2023 and has held it in 13 quarters since.
  • Ballentine Partners's ResMed position peaked at $800K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.